# Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

> **NCT04696731** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Allogene Therapeutics** · enrollment: 120 (estimated)

## Conditions studied

- Advanced/Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **GENETIC:** ALLO-316
- **BIOLOGICAL:** ALLO-647
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04696731
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-24
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04696731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04696731, "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04696731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*